Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Thulium Fiber Laser Versus Holmium MOSES™ Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Prospective Clinical Study - Beyond the Abstract ...

Immunohistochemical Expression of Nectin-4 and Potential Implications for Enfortumab Vedotin Therapy in Germ Cell Tumors of the Testis: A Preliminary Study - Beyond the Abstract ...

Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer. February 6, 2026 Updated 5-year Survival ...

2025 in Review: Evaluating the Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer Sent on 29 December 2025 2025 in Review: Optimized Use of Radioligand Therapy in mCRPCSent on 27 ...

While immune checkpoint inhibition has reshaped the treatment of multiple solid tumors, prostate cancer has remained largely refractory to therapies directed against PD-1, PD-L1, or CTLA-4. In ...

Urobiome Analysis in Interstitial Cystitis/Bladder Pain Syndrome Reveals Nuanced Differences Associated with Localized Pain. January 11, 2026 Exploring the molecular link between obstructive sleep ...

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no ...